Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Kraml

Showing results (41-50 of 64) with videos related to

Pageof 7
Sort By:
Journal of Clinical Pharmacology|November 1, 1981
Comparative bioavailability of propranolol: twice-daily versus four times-daily administrationD Dvornik, M Kraml, J Dubuc, et al.
Clinical Pharmacology and Therapeutics|October 1, 1984
Tolrestat kineticsD R Hicks, M Kraml, M N Cayen, et al.
Clinical Pharmacology and Therapeutics|March 1, 1994
Concomitant etodolac affects neither the unbound clearance nor the pharmacologic effect of warfarinJ C Ermer, D R Hicks, S C Wheeler, et al.
Journal of the American Chemical Society|September 10, 2004
A pentacene with a 144 degrees twistJun Lu, Douglas M Ho, Nancy J Vogelaar, et al.
Biopharmaceutics & Drug Disposition|January 1, 1984
Bioavailability studies with etodolac in dogs and manM Kraml, L Cosyns, D R Hicks, et al.
Chemistry (Weinheim an Der Bergstrasse, Germany)|September 8, 2011
The catalytic asymmetric Diels-Alder reactions and post-cycloaddition reductive transpositions of 1-hydrazinodienesHao Xie, Glenn M Sammis, Eric M Flamme, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 1, 1985
Metabolic disposition and pharmacokinetics of the aldose reductase inhibitor tolrestat in rats, dogs, and monkeysM N Cayen, D R Hicks, E S Ferdinandi, et al.
Photochemistry and Photobiology|January 1, 1992
Phototoxic and photochemical properties of sanguinarineJ T Arnason, B Guèrin, M M Kraml, et al.
Biopharmaceutics & Drug Disposition|January 1, 1982
Biopharmaceutical characteristics of a new propranolol/hydrochlorothiazide tablet combinationM Kraml, J Dubuc, D Dvornik, et al.
Clinical Pharmacology and Therapeutics|June 1, 1996
Pharmacokinetics of the aldose reductase inhibitor tolrestat: studies in healthy young and elderly male and female subjects and in subjects with diabetesR Fruncillo, S Troy, V Parker, et al.
Pageof 7

Showing results (41-50 of 64) with videos related to

Sort By:
Pageof 7
Journal of Clinical Pharmacology|November 1, 1981
Comparative bioavailability of propranolol: twice-daily versus four times-daily administrationD Dvornik, M Kraml, J Dubuc, et al.
Clinical Pharmacology and Therapeutics|October 1, 1984
Tolrestat kineticsD R Hicks, M Kraml, M N Cayen, et al.
Clinical Pharmacology and Therapeutics|March 1, 1994
Concomitant etodolac affects neither the unbound clearance nor the pharmacologic effect of warfarinJ C Ermer, D R Hicks, S C Wheeler, et al.
Journal of the American Chemical Society|September 10, 2004
A pentacene with a 144 degrees twistJun Lu, Douglas M Ho, Nancy J Vogelaar, et al.
Biopharmaceutics & Drug Disposition|January 1, 1984
Bioavailability studies with etodolac in dogs and manM Kraml, L Cosyns, D R Hicks, et al.
Chemistry (Weinheim an Der Bergstrasse, Germany)|September 8, 2011
The catalytic asymmetric Diels-Alder reactions and post-cycloaddition reductive transpositions of 1-hydrazinodienesHao Xie, Glenn M Sammis, Eric M Flamme, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 1, 1985
Metabolic disposition and pharmacokinetics of the aldose reductase inhibitor tolrestat in rats, dogs, and monkeysM N Cayen, D R Hicks, E S Ferdinandi, et al.
Photochemistry and Photobiology|January 1, 1992
Phototoxic and photochemical properties of sanguinarineJ T Arnason, B Guèrin, M M Kraml, et al.
Biopharmaceutics & Drug Disposition|January 1, 1982
Biopharmaceutical characteristics of a new propranolol/hydrochlorothiazide tablet combinationM Kraml, J Dubuc, D Dvornik, et al.
Clinical Pharmacology and Therapeutics|June 1, 1996
Pharmacokinetics of the aldose reductase inhibitor tolrestat: studies in healthy young and elderly male and female subjects and in subjects with diabetesR Fruncillo, S Troy, V Parker, et al.
Pageof 7